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Dengue, a global health threat, is a leading cause of morbidity and mortality in most tropical and subtropical
countries. Dengue can range from asymptomatic, relatively mild dengue fever to severe and life-threatening
dengue hemorrhagic fever. Disease severity and outcome is largely associated with the host immune response.
Several candidate vaccines in clinical trials appear promising as effective measures for dengue disease control.
Vaccine development has been hampered by safety and efficacy issues, driven by a lack of understanding of the
host immune response. This review focuses on recent research findings on the dengue host immune response,
particularly in humans, and the relevance of these findings to challenges in vaccine development.
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Dengue virus (DENV) annually infects up to 390 million
people living in tropical and subtropical areas [1]. It is
estimated that up to half of the world’s population is at
risk for DENV infection [2]. In recent years, several
countries with subtropical regions, including France,
Croatia, and Taiwan, reported autochthonous transmis-
sion of DENV [3–5]. DENV cases in Japan have been on
the rise; 9 imported cases were reported in 1999 but in-
creased to 249 cases in 2013. In 2014, the first autoch-
thonous DENV transmission in 70 years was reported in
Japan, where a total of 162 local DENV patients were re-
ported. In addition, there were 179 imported cases in
2014, bringing the total DENV cases in 2014 to 341, the
highest number of cases in recent years [6, 7]. Factors
contributing to the rapidly increasing DENV cases over
the past 70 years include expanding habitats of the mos-
quito vectors, Aedes aegypti and Aedes albopictus, due
to urbanization and climate change, and increase in
population. A. aegypti, a mosquito prevalent in the tro-
pics, is closely associated with large dengue epidemics
due to its ability to efficiently transmit DENV. In con-
trast, the habitat range of A. albopictus is not limited to
the tropics but includes the temperate subtropical* Correspondence: sherry@nagasaki-u.ac.jp
1Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan
2National Institute of Infectious Diseases, Tokyo, Japan
© 2016 Moi et al. Open Access This article is
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zeregions of Europe, North America, and East Asia. Be-
cause of the widespread distribution of A. albopictus,
there is a potential threat of dengue spreading to wider
geographical areas.
DENV belongs to the genus Flaviviridae, a group
comprised of antigenically closely related viruses that
cause disease in humans, including the Japanese enceph-
alitis virus (JEV), yellow fever virus (YFV), and West
Nile virus (WNV). The genome of DENV is a single,
plus-stranded RNA which encodes three structural pro-
teins (capsid [C], envelope [E], and preM proteins) and
seven nonstructural proteins (NS1, NS2A, NS2B, NS3,
NS4A, NS4B, and NS5). Infection with any of the four
DENV serotypes that are antigenically and genetically re-
lated causes symptoms ranging from acute febrile illness
to severe manifestations that include bleeding and organ
failure. Without appropriate treatment, the mortality
rate of dengue hemorrhagic fever (DHF) is approxi-
mately 25 %. Currently, there is no specific treatment or
vaccine for dengue.Clinical signs of dengue
DENV causes a wide range of clinical symptoms, ranging
from asymptomatic infection and dengue fever (DF) to
the severe forms of illness, DHF, and dengue shock syn-
drome (DSS). Symptoms typically appear 4–7 days after
an incubation period following a bite from an infecteddistributed under the terms of the Creative Commons Attribution 4.0
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ized by a sudden onset of fever accompanied by a gener-
alized morbilliform rash, headache, myalgias, and retro-
orbital pain during the acute phase. The febrile phase
generally lasts for a week. Symptoms are also accompan-
ied by thrombocytopenia and leukopenia. A small pro-
portion of dengue patients develop severe dengue (DHF
or DSS). In severe dengue, life-threatening symptoms of
plasma leakage, severe thrombocytopenia, hemorrhagic
manifestations, and coagulation disorders may lead to
shock and multiple organ failure during the critical
phase of the disease. After the critical phase, most pa-
tients recover without any sequelae, although some de-
velop fatigue and depression that lasts for several weeks
after the acute phase. In severe dengue, an estimated
500,000 require hospitalization, and the mortality rate is
2.5 %, particularly in infants and young children [2].
Atypical clinical signs and symptoms of dengue include
encephalitis, myocarditis, and respiratory distress [8].
Host immune responses to DENV
Humoral and cellular immune responses may play im-
portant roles in both disease pathogenesis and protec-
tion [9–12]. The paradoxical role of the host immune
response in disease outcome is associated with consecu-
tive infection by two different DENV serotypes. There
are four serotypes of DENV, characterized by their anti-
genicity. The basis for host immunity in the disease out-
come involves (1) virus-neutralizing antibodies directed
against viral proteins and (2) immune cascades triggered
by viral epitope-activated memory T cells [9–12].
Epidemiological studies have found that primary den-
gue patients, after a short cross-protective period, are at
higher risk of developing severe dengue during a con-
secutive infection with another DENV serotype [12, 13].
The increased risk of developing severe dengue is hy-
pothesized to be associated with non-protective serotype
cross-reactive immunity induced after primary DENV
infection. The basis for this is that after a primary DENV
infection, serotype cross-reactive protective immunity
wanes over a few months [14]. Neutralization activity
in vitro was absent in diluted patient serum samples, in-
dicating that a certain antibody threshold is needed for
virus neutralization [14, 15]. Although serotype cross-
reactive neutralizing antibodies confer protection at a
certain threshold, waning immunity or a decline in anti-
body concentration induces susceptibility to infection
with another DENV serotype.
Upon secondary infection with a heterogeneic serotype
during this period of waning immunity, homotypic
serotype-specific memory T and B cells are activated.
This early serotype-specific immunity is directed against
infection by the prior DENV serotype, but not to the
current infecting serotype [9, 10]. During secondaryinfection, T cell responses directed against the previous
infecting serotype do not confer protection and are asso-
ciated with the triggering of immune cascades that in-
duce severe symptoms [9].
As the disease progresses to the convalescent phase,
serotype cross-reactive immunity with high avidity to all
four DENV serotypes develops. These broadly reactive
antibodies confer protection to all four DENV serotypes.
A third or fourth infection may occur in hyperendemic
areas, although a majority of these infections are hypoth-
esized to be asymptomatic or mild [11].
Role of antibodies in pathogenesis of severe dengue
Epidemiological evidence has demonstrated that two
groups of individuals are at higher risk of developing severe
dengue: (1) adults with waning homotypic immunity and
(2) infants born to dengue-immune mothers [13–15].
Serum samples obtained from these individuals during the
period of waning immunity were found to enhance DENV
infection in vitro [16]. Antibodies in these serum samples
possess the ability to enhance DENV infection of Fcgamma
(FcγR)-bearing cells in a phenomenon known as antibody-
dependent enhancement (ADE) [16–20]. In ADE, subneu-
tralizing levels of antibodies form a virus immune complex
that enhances the infection of DENV target cells, the FcγR-
bearing hematopoietic cell lines, leading to high levels of
viremia [21–23]. Viremia determined by FcγR-bearing cells
is up to 10 times greater than that determined by non-
FcγR-bearing cells [13]. The resulting high level of viremia
triggers the immune system, which in turn is associated
with increased disease severity [22, 23].
Serum samples from convalescent DENV patients typ-
ically demonstrate ADE activity at higher dilutions and
neutralizing activity at lower dilutions, indicating that
antibodies induced after infection possess two contrast-
ing activities [17]. In patients with acute secondary infec-
tion, undiluted serum samples demonstrated ADE
activity against the infecting serotype, suggesting that
ADE occurs in vivo [14–16]. ADE has also been demon-
strated in animal models of secondary infection, in ani-
mals passively transferred with infection-enhancement
antibodies, and in a maternally acquired heterotypic
dengue antibody animal model [24–27].
Antibodies in protection against DENV infection
Neutralizing antibodies are considered central in protec-
tion against DENV infection. Antibodies targeting
DENV possess two competing activities related to patho-
genicity: virus neutralization and infection enhancement.
At higher avidity, antibodies neutralize DENV, whereas
lower levels of antibodies enhance DENV infection and
hamper virus neutralization [17]. The concept was con-
firmed in studies of serum samples from dengue pa-
tients, in which neutralizing activity was present to
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cells, but ADE activity that lowers the overall neutraliz-
ing activity was present to the current infecting serotype
(DENV-1 and DENV-3), as demonstrated by FcγR-
expressing cells (Table 1) [17]. After the cross-protection
phase in patients with primary infection, antibodies
demonstrate high levels of neutralizing activity to a
homotypic serotype, but neutralizing activity against
other serotypes is absent. Antibodies with high neutraliz-
ing activity to the prior infecting serotype also demon-
strate cross-reactivity to other serotypes as well as
infection-enhancement activity [7].
After acute infection, a high proportion of the anti-
bodies is directed against the E protein, and some target
the prM and NS1 proteins. The virion envelope is a lipid
bilayer, which consists of the E and M proteins. A majority
of the induced antibodies target the E protein; therefore,
virus neutralization may involve neutralization of the E
protein epitopes. The antibodies induced consistently
react with the E protein, but there is variability in the re-
activity to domains I, II, and III; the considerable variabil-
ity in reactivity in each of the domains isolated from
individual patients indicates that virus neutralization may
involve several epitopes [28, 29].
In DENV hyperendemic regions, co-circulation of sev-
eral serotypes demonstrates an epidemiological pattern
in which outbreaks arise from a dominant serotype, in a
2–4-year cycle [30, 31]. These cycles persist because in-
fection with one serotype confers only partial protection
and may be driven by low immunity to each of the den-
gue serotypes, which then allows the virus to persist in
the region. In hyperendemic regions, most adults are ex-
posed to two or more serotypes and demonstrate
seroconversion.
Determination of neutralizing activity of an antibody to
DENV
As neutralizing activity of an antibody is considered cen-
tral in providing protection against dengue, levels of
neutralizing antibody have been used as a proxy for dis-
ease protection. Determination of levels of neutralizing







DENV neutralizing antibody titer (PRNT50)
BHK cells
DENV-1 DENV-2 DENV-3
DENV-1 (7) 3b 10–80 10–1280 <10–20
4 <10 10–320 <10
DENV-3 (10) 8b 10–80 <10–1280 10–40
2 <10 80–160 <10
Data source [17]
aIndicates the total number of patients
bIndicates the number of patients with neutralizing antibody to infecting serotype aresponse after vaccination. Neutralizing antibody to den-
gue is determined by using the plaque reduction
neutralization test (PRNT). The PRNT is regarded as
the gold standard for determination of neutralizing anti-
bodies [32]. High titers of neutralizing antibody titers
are associated with protection against subsequent DENV
infection. However, infection-enhancement activity has
been demonstrated to lower neutralizing activity of anti-
bodies in the presence of FcγR [17, 33]. Thus, the use of
non-FcγR-bearing cells for assays poses a challenge in
defining the true serological correlate to DENV protec-
tion in vivo and in vaccine efficacy trials. Because FcγR-
bearing monocyte-lineage cells are the major targets of
DENV infection in vivo, these cells may better reflect
the biological properties of neutralizing antibodies [34].
Primary and established monocyte-lineage cell lines have
also been used in neutralization tests [14, 15, 35–38].
Although assays to determine neutralization antibody
titers have been developed, the correlate of protection
for dengue has yet to be defined. For JEV, a titer of
≥1:10 at PRNT50 has been suggested as a threshold that
demonstrates protection [39, 40]. For DENV, titers of
≥1:10 have been demonstrated in convalescent serum
samples, but the cutoff has not been determined. Deter-
mination of cutoff titer that demonstrates protection is
needed to better predict vaccine efficacy.
Although the PRNT is the most reliable test to deter-
mine neutralizing antibodies, it is laborious and requires
skilled personnel. Considering the magnitude of the den-
gue problem, standardized high-throughput assays are
needed for both research and industrial settings. Early
studies using flow cytometry, peroxidase-antiperoxidase
(PAP) and an enzyme-linked immunosorbent assay
(ELISA) that employs FcγR-expressing cells have proved
useful in the determination of neutralizing activity of
DENV antibodies [35–38]. Tools that use the viral pro-
tein subunits and E protein epitopes are promising, as
these tests are rapid compared to the PRNT [41, 42].
However, further studies are needed to validate these
tests and the results compared to those of the conven-
tional PRNT, to establish a robust immune correlate for
disease protection [32].determined by FcγR-expressing BHK cells
FcγR-expressing BHK cells
DENV-4 DENV-1 DENV-2 DENV-3 DENV-4
<10–20 <10 <10–160 <10 <10
<10 <10 <10–40 <10 <10
<10–40 <10–20 <10–80 <10 <10
<10 <10 20–40 <10 <10
s determined by non FcγR-expressing cells
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antibody response for DENV vaccine design
Currently, there are no licensed dengue vaccine which
are used clinically. Dengue vaccine research has been
carried out for the past 70 years, beginning with the first
isolation of the virus during epidemics in Hawaii and
Japan. Within a few decades, live-attenuated virus, inac-
tivated vaccine, chimeric flavivirus, DNA, and subunit
vaccines have been developed (Table 2). However, vac-
cine immunogenicity, safety, and efficacy have been re-
curring issues in their use for control of the disease.
Additional challenges hampering clinical development
include the lack of a robust immune correlate for den-
gue, possible inhibitory or enhancing effects that are in-
duced upon natural flavivirus infection and vaccination,
and the need for definition of vaccine trial endpoints.
The observation of the development of severe dengue
during heterotypic secondary infection implies the need
for a vaccine that possesses the ability to simultaneously
induce long-term protective immunity to all four sero-
types. Multiple vaccine formulations are currently under
development, and several candidates are currently in
preclinical and clinical stages. Currently, the live-
attenuated tetravalent chimeric YFV/DENV vaccine
(CYD-TDV) is in the most advanced clinical trial stage
(phase III) [43]. The phase I and II studies of the CYD-
TDV vaccine have demonstrated that it is safe and toler-
ated, with confirmation of seroconversion and virological
efficacy [44]. In multisite phase III clinical trials con-
ducted in Asia and Latin America, the overall efficacy of
the CYD-TDV candidate vaccine ranges from 30 to 64 %
against DENV infection. The incidence of severe dengueTable 2 Characteristics of candidate tetravalent dengue vaccines in































WRAIR, GSK TDENV-PIV Whole purified inact
Subunit
vaccine
Merck (Hawaiian Biotech) DENV-
V180
Truncated DENV E p
DNA vaccine U.S. Army Medical
Research and Material
Command/WRAIR
TVDV Plasmids encoding t
aIndicates no data(>80 % efficacy) and hospitalization was also lower in
the vaccine cohort study. Surprisingly, vaccine efficacy
against DENV-2 in comparison to the other serotypes
was consistently low, ranging from 9 to 42 % [43–46].
The overall efficacy also varied with study site, suggesting
that efficacy may be associated with epidemiological pat-
terns and the host immunity baseline. While a lower inci-
dence of severe dengue was seen in the vaccine cohort,
results from the study demonstrated that seroconversion
did not consistently reflect protective immunity [44].
Recent DENV vaccine clinical trials and patient cohort
studies have found that despite the presence of serocon-
version (PRNT50 >1:20) in vaccines, protection against
DENV-2 was minimal [44]. Although conventional
PRNT assays used in these studies are considered reli-
able in determining neutralizing antibodies as a proxy
for disease protection, the assay uses FcγR-negative cells.
A novel PRNT assay has demonstrated that neutralizing
activity of some serum samples from dengue patients
was absent or present at much lower titers when deter-
mined using FcγR-expressing BHK cells, as compared to
non-FcγR-bearing cells [17]. Interestingly, neutralizing
activity to the current infecting serotype was not de-
tected by using FcγR-bearing cells but was present when
non-FcγR-bearing cells were used for the assay (Table 1).
These studies suggest that DENV-2 infection break-
through despite seroconversion could be caused by the
dominance of antibodies that might not confer virus
neutralization in the presence of FcγR.
Alternatively, it is hypothesized that neutralizing activ-
ity of an antibody displays differential activity against







vaccine with yellow fever 17D vaccine strain as
itution of preM and E protein genes with each
rotype
PIII 56.5–60.8 %
vaccine with DENV-2 as backbone and substi-
E protein genes of DENV-1, DENV-3, and DENV-
PII –1
nt formulation with a deletion of 30
UTR of DENV-1, DENV-3 (or chimeric DENV-3/
d a chimeric DENV-2/DENV-4
PII –
strains by serial passages in PDK cells PII –
ivated vaccine PI –
rotein PI –
he prM/E genes of each DENV serotype PI –
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Asian and American DENV-2 strains are induced after
exposure to DENV-1 [47, 48]. Although multiple geno-
types exist in a DENV serotype, the differences in the
antigenicity of each genotype in relation to the resulting
protection against different genotypes need further
characterization.
In addition to protective efficacy issues, hypothetical
safety concerns include (1) possible enhancement of
clinical response to live-attenuated vaccine in individuals
with a flavivirus-immune background, (2) non-protective
or waning immunity in vaccinated individuals that could
potentially increase the risk of severe dengue, and (3) in-
sufficient attenuation of vaccine strains. The CYD-TDV
candidate vaccine trial has demonstrated that the vac-
cine is safe, and efficacy has been demonstrated through
lesser number of virologically confirmed cases within
the 2-year study period [46]. However, long-term results
would provide insights into waning immunity in vacci-
nated individuals and the risk of severe dengue [45].
Additionally, further studies on the immune response to
dengue vaccines in non-endemic areas would provide a
better understanding of the host immune response in in-
dividuals without a dengue-immune background.
With half of the world population at risk of DENV infec-
tion, an effective dengue vaccine that confers long-term
protective immunity to all four dengue serotypes would
contribute significantly to disease control. Other consider-
ations in dengue disease control would include suitability of
the vaccination program, cost constraints, and identifica-
tion of disease burden. The CYD-TDV (Dengvaxia) vaccine
has been approved as the first registered dengue vaccine in
Mexico in December 2015. The CYD-TDV vaccine is also
currently under review for clinical introduction in other en-
demic regions and is anticipated to reduce dengue burden.
Follow-up observations on the CYD-TDV vaccine efficacy
would however be needed, particularly on breakthrough in-
fections and severe dengue in vaccine recipients. Other
promising vaccine candidates in clinical and preclinical tri-
als include virus-vectored and VLP-based vaccines. These
next-generation vaccine candidates may offer improved ap-
proaches to disease control as they have been demonstrated
to be safe due to the non-infectious nature of the vaccine,
highly immunogenic, and could be modified rapidly to
match recent epidemic strains. With dengue disease burden
being the highest in developing countries, a cost-effective,
safe vaccine that confers protection with a single dose
would be ideal in disease control programs.
Conclusions
Dengue epidemics continue to be a serious public health
problem in many areas of the world. Disease control re-
mains a challenge in the absence of a vaccine and spe-
cific therapies. Development of tools and robust animalmodels to advance understanding of the host immune
response will facilitate a better understanding of vaccine
efficacy and safety issues and contribute to the develop-
ment of dengue vaccine and treatment programs.
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